From company headquarters in Stockholm, Sweden, Genagon is researching, developing and pre-clinically testing novel drug delivery proteins that offer extraordinary opportunities to fight a large variety of hitherto untreatable solid tumors. Our ADCs are potent biopharmaceuticals that both kill cancer cells and pave the way for complete tumor clearance, thus significantly decreasing the risk of future relapses. Moreover, ADCs display not only high efficacy, they are also very cost-effective.
As an astute, goal-oriented company, we are committed to developing/advancing these new therapeutic opportunities into real clinical benefits and increased hope for cancer patients. Our patent portfolio is strong, and we receive sound financial support from major Swedish investors.
To increase treatment efficacy and periods of remission for cancer patients and in the future, give people a chance to live cancer-free.
Provide next generation ADCs for indications with high unmet clinical need.
Genagon identifies novel targets for antibody targeted therapy in cancer, working in the exciting emerging field of antibody drug conjugates.
We have a highly devoted and skilled team conducting research and development. We have a unique research competence in antibody validation and characterization that accelerates the selection process of our lead antibody assets. We have many collaborations worldwide, but at Genagon we coordinate and evaluate the important results. Our mission is to bring new therapies into the clinic and in the long run become one of the companies that contribute with new innovations and treatments in the fight against cancer.
There is an arising interest from the pharmaceutical sector and Genagon has got a lot of traction for our ADC assets in the breast cancer area. During the coming year we will start cell line development and the clinical production of our lead candidate ADC. Bringing the next generation of ADCs to the clinic is one important mission.
The best part of Genagon is the highly devoted and skilled team of researchers conducting the research and development. We have a unique competence in antibody validation and characterization that accelerates the selection process of our lead antibody assets.